Osilodrostat - Recordati
Alternative Names: Isturisa; LCI-699Latest Information Update: 05 Feb 2026
At a glance
- Originator Novartis
- Developer Novartis; Recordati
- Class Antihypertensives; Antineoplastics; Antisecretories; Corticosteroids; Fluorobenzenes; Heart failure therapies; Imidazoles; Nitriles; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action Cytochrome P-450 CYP11B2 inhibitors; Steroid 11-beta-hydroxylase inhibitors
-
Orphan Drug Status
Yes - Pituitary ACTH hypersecretion; Cushing syndrome
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cushing syndrome; Pituitary ACTH hypersecretion
- Discontinued Heart failure; Hypertension; Solid tumours